Loading...
Market
Story
Illumina to Spin Off Grail in June, Retains 14.5 Percent Stake
Jun 3, 2024, 11:05 PM
Illumina Inc. has officially announced the spin-off of its cancer test subsidiary, Grail. The board of directors approved the spin-off, marking the end of a nearly four-year-long saga. As part of the divestment, Illumina will issue Grail shares to its investors while retaining a 14.5 percent stake in the company. Additionally, the board declared a spin-off dividend of Grail shares. The spin-off is set to be completed in June.
View original story
Similar markets
Under $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
Above $2 billion • 25%
Below $10 billion • 25%
$10 billion - $15 billion • 25%
$15 billion - $20 billion • 25%
Above $20 billion • 25%
Below $2 billion • 33%
$2 billion to $3 billion • 33%
Above $3 billion • 34%
Below $3.5 billion • 25%
$3.5 billion to $4 billion • 25%
$4 billion to $4.5 billion • 25%
Above $4.5 billion • 25%
Below $2 billion • 25%
$2 billion to $4 billion • 25%
$4 billion to $6 billion • 25%
Above $6 billion • 25%
Below $2.7 billion • 25%
Between $2.7 billion and $3.5 billion • 25%
Between $3.5 billion and $4.5 billion • 25%
Above $4.5 billion • 25%
Below $300B • 25%
$300B to $350B • 25%
$350B to $400B • 25%
Above $400B • 25%
Below $30 billion • 33%
$30 billion to $50 billion • 33%
Above $50 billion • 34%
Less than $500 billion • 25%
$500 billion to $750 billion • 25%
$750 billion to $1 trillion • 25%
More than $1 trillion • 25%
$2.5 million - $5 million • 25%
$5.1 million - $10 million • 25%
$10.1 million - $20 million • 25%
Over $20 million • 25%